BioNTech To Supply 100M Coronavirus Vaccine Doses To Chinese Partner Fosun Pharma

Financial Times: BioNTech set to become first foreign jab to enter China market
“BioNTech will supply 100m doses of its coronavirus vaccine to Chinese partner Fosun Pharma for use in mainland China next year in the country’s first publicly announced order of a foreign jab against the disease…” (Shepherd, 12/16).

Additional coverage of the agreement is available from Bloomberg.

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.